Marchex Q2 2026: Revenue Down 6%, Archenia Deal Terms Revealed
MCHX sits 38% above its 52-week low of $1.322 on elevated volume (2.5× avg).
Summary
Marchex reported Q2 revenue of $11.0M, down 6% YoY, and a net loss of $0.4M. The 10-Q details the Archenia acquisition terms and Telmetrics settlement.
Key Events · Earnings and Guidance · MCHX
-
Q2 Revenue Declines 6%
Revenue was $11.0M for Q2 2026, down from $11.7M in Q2 2025. Net loss was $0.4M vs. a profit of $0.1M a year ago.
-
Archenia Acquisition Terms
Marchex issued $10.0M in 6% convertible notes, convertible at $1.80/share, and may issue up to 2.0M Class B shares per year for two years as earnout.
-
Telmetrics Litigation Settled
Settlement of $2.0M: $1.0M paid May 14, 2026, and $500K due Nov 16, 2026 and May 17, 2027. $1.0M remains accrued.
-
Cash Position
Cash and equivalents fell to $8.2M from $9.9M at year-end. Management states resources are sufficient for at least 12 months.
Analysis · MCHX · Technology
Marchex's Q2 revenue fell 6% to $11.0M, swinging to a net loss of $0.4M. The 10-Q reveals the full terms of the Archenia acquisition: $10M in convertible notes at $1.80/share plus up to 4M earnout shares, which could dilute existing holders. The company also settled the Telmetrics litigation for $2.0M, with $1.0M remaining to be paid. Cash declined to $8.2M, but management believes resources are sufficient for at least 12 months.
At the time of this filing, MCHX was trading at $1.82 on NASDAQ in the Technology sector, with a market capitalization of approximately $80.7M. The 52-week trading range was $1.32 to $2.09. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.